Cargando…

Case Report: Adjuvant Crizotinib Therapy Exerted Favorable Survival Benefit in a Resectable Stage IIIA NSCLC Patient With Novel LDLR–ROS1 Fusion

Novel adjuvant strategies are needed to optimize outcomes after complete surgical resection in patients with early-stage non-small-cell lung cancer (NSCLC). The adjuvant treatment of ROS Proto-Oncogene 1 (ROS1) fusion-positive resected NSCLC is challenging because there is no curative confirmed rand...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, An-guo, Chen, Dong-sheng, Li, Si, Zhao, Le-le, Xiao, Ming-zhe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921990/
https://www.ncbi.nlm.nih.gov/pubmed/35299735
http://dx.doi.org/10.3389/fonc.2022.837219
_version_ 1784669433679052800
author Chen, An-guo
Chen, Dong-sheng
Li, Si
Zhao, Le-le
Xiao, Ming-zhe
author_facet Chen, An-guo
Chen, Dong-sheng
Li, Si
Zhao, Le-le
Xiao, Ming-zhe
author_sort Chen, An-guo
collection PubMed
description Novel adjuvant strategies are needed to optimize outcomes after complete surgical resection in patients with early-stage non-small-cell lung cancer (NSCLC). The adjuvant treatment of ROS Proto-Oncogene 1 (ROS1) fusion-positive resected NSCLC is challenging because there is no curative confirmed randomized controlled trial. Next-generation sequencing (NGS) and immunohistochemistry (IHC) staining were performed on the biopsy sample. In this case, we identified a novel LDLR–ROS1 fusion in a resectable stage IIIA NSCLC patient. The patient received crizotinib as adjuvant treatment and achieved recurrence-free survival (RFS) for 29 months, without significant symptoms of toxicity. In this case, we report a novel LDLR–ROS1 fusion responding to crizotinib in a patient with lung adenocarcinoma, supporting the use of adjuvant treatment with the ROS1 inhibitor exerting clinical survival benefit in ROS1 fusion-positive resected NSCLC.
format Online
Article
Text
id pubmed-8921990
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89219902022-03-16 Case Report: Adjuvant Crizotinib Therapy Exerted Favorable Survival Benefit in a Resectable Stage IIIA NSCLC Patient With Novel LDLR–ROS1 Fusion Chen, An-guo Chen, Dong-sheng Li, Si Zhao, Le-le Xiao, Ming-zhe Front Oncol Oncology Novel adjuvant strategies are needed to optimize outcomes after complete surgical resection in patients with early-stage non-small-cell lung cancer (NSCLC). The adjuvant treatment of ROS Proto-Oncogene 1 (ROS1) fusion-positive resected NSCLC is challenging because there is no curative confirmed randomized controlled trial. Next-generation sequencing (NGS) and immunohistochemistry (IHC) staining were performed on the biopsy sample. In this case, we identified a novel LDLR–ROS1 fusion in a resectable stage IIIA NSCLC patient. The patient received crizotinib as adjuvant treatment and achieved recurrence-free survival (RFS) for 29 months, without significant symptoms of toxicity. In this case, we report a novel LDLR–ROS1 fusion responding to crizotinib in a patient with lung adenocarcinoma, supporting the use of adjuvant treatment with the ROS1 inhibitor exerting clinical survival benefit in ROS1 fusion-positive resected NSCLC. Frontiers Media S.A. 2022-03-01 /pmc/articles/PMC8921990/ /pubmed/35299735 http://dx.doi.org/10.3389/fonc.2022.837219 Text en Copyright © 2022 Chen, Chen, Li, Zhao and Xiao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Chen, An-guo
Chen, Dong-sheng
Li, Si
Zhao, Le-le
Xiao, Ming-zhe
Case Report: Adjuvant Crizotinib Therapy Exerted Favorable Survival Benefit in a Resectable Stage IIIA NSCLC Patient With Novel LDLR–ROS1 Fusion
title Case Report: Adjuvant Crizotinib Therapy Exerted Favorable Survival Benefit in a Resectable Stage IIIA NSCLC Patient With Novel LDLR–ROS1 Fusion
title_full Case Report: Adjuvant Crizotinib Therapy Exerted Favorable Survival Benefit in a Resectable Stage IIIA NSCLC Patient With Novel LDLR–ROS1 Fusion
title_fullStr Case Report: Adjuvant Crizotinib Therapy Exerted Favorable Survival Benefit in a Resectable Stage IIIA NSCLC Patient With Novel LDLR–ROS1 Fusion
title_full_unstemmed Case Report: Adjuvant Crizotinib Therapy Exerted Favorable Survival Benefit in a Resectable Stage IIIA NSCLC Patient With Novel LDLR–ROS1 Fusion
title_short Case Report: Adjuvant Crizotinib Therapy Exerted Favorable Survival Benefit in a Resectable Stage IIIA NSCLC Patient With Novel LDLR–ROS1 Fusion
title_sort case report: adjuvant crizotinib therapy exerted favorable survival benefit in a resectable stage iiia nsclc patient with novel ldlr–ros1 fusion
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921990/
https://www.ncbi.nlm.nih.gov/pubmed/35299735
http://dx.doi.org/10.3389/fonc.2022.837219
work_keys_str_mv AT chenanguo casereportadjuvantcrizotinibtherapyexertedfavorablesurvivalbenefitinaresectablestageiiiansclcpatientwithnovelldlrros1fusion
AT chendongsheng casereportadjuvantcrizotinibtherapyexertedfavorablesurvivalbenefitinaresectablestageiiiansclcpatientwithnovelldlrros1fusion
AT lisi casereportadjuvantcrizotinibtherapyexertedfavorablesurvivalbenefitinaresectablestageiiiansclcpatientwithnovelldlrros1fusion
AT zhaolele casereportadjuvantcrizotinibtherapyexertedfavorablesurvivalbenefitinaresectablestageiiiansclcpatientwithnovelldlrros1fusion
AT xiaomingzhe casereportadjuvantcrizotinibtherapyexertedfavorablesurvivalbenefitinaresectablestageiiiansclcpatientwithnovelldlrros1fusion